Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalTherapeutic Innovation and Regulatory Science
Volume50
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Drug Discovery
Reward
Pharmaceutical Preparations
Japan
Neurosciences
Therapeutics
Orphan Drug Production
Pharmaceutical Databases
Off-Label Use
Allergy and Immunology
Motivation

Keywords

  • drug development
  • global pharmaceutical companies
  • Japanese pharmaceutical companies
  • marketing strategy
  • pricing

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{cfddb125f79b4c56afc2848ca25615e4,
title = "Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area",
abstract = "Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.",
keywords = "drug development, global pharmaceutical companies, Japanese pharmaceutical companies, marketing strategy, pricing",
author = "Shoyo Shibata and Ryotaro Uemura and Takeshi Suzuki",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/2168479015600205",
language = "English",
volume = "50",
pages = "49--55",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market

T2 - An Analysis by Therapeutic Area

AU - Shibata, Shoyo

AU - Uemura, Ryotaro

AU - Suzuki, Takeshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.

AB - Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.

KW - drug development

KW - global pharmaceutical companies

KW - Japanese pharmaceutical companies

KW - marketing strategy

KW - pricing

UR - http://www.scopus.com/inward/record.url?scp=84952777268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952777268&partnerID=8YFLogxK

U2 - 10.1177/2168479015600205

DO - 10.1177/2168479015600205

M3 - Article

AN - SCOPUS:84952777268

VL - 50

SP - 49

EP - 55

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 1

ER -